![Ronald Stafford Watts](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Ronald Stafford Watts
Direttore/Membro del Consiglio presso Wenkart Foundation
Posizioni attive di Ronald Stafford Watts
Società | Posizione | Inizio | Fine |
---|---|---|---|
Wenkart Foundation | Direttore/Membro del Consiglio | - | - |
Biosceptre International Ltd.
![]() Biosceptre International Ltd. BiotechnologyHealth Technology Part of Biosceptre (Aust) Pty Ltd., Biosceptre International Ltd. is a biopharmaceutical company based in Babraham, UK. The British company is focused on developing their BRiDGECAR™ system, which combines nfP2X7-targeted technology with highly potent chimeric antigen receptor (CAR) T-cell therapy and multiple targeted antibodies. The company's researchers are pioneers in cancer therapeutic development, with a vision of targeted treatment for millions of cancer patients across the world. The company's multi-targeted BRiDGECAR™ system has the potential to benefit a range of malignancies and make a drastic difference to the lives of millions of cancer patients. The company's advisory board includes Sir Gregory Winter, a 2018 Nobel Prize winner in Chemistry. | Direttore/Membro del Consiglio | - | - |
Storia della carriera di Ronald Stafford Watts
Precedenti posizioni note di Ronald Stafford Watts
Società | Posizione | Inizio | Fine |
---|---|---|---|
ENERGY ACTION LIMITED | Direttore/Membro del Consiglio | 12/11/2015 | 30/06/2017 |
Presidente | 14/10/2011 | 12/11/2015 | |
Biosceptre (Aust) Pty Ltd.
![]() Biosceptre (Aust) Pty Ltd. Pharmaceuticals: MajorHealth Technology Biosceptre (Aust) Pty Ltd. develops and commercializes antibody technologies for applications in the diagnosis and treatment of cancer. The company was founded in 2000 and is headquartered in North Ryde, Australia. | Direttore/Membro del Consiglio | - | - |
Formazione di Ronald Stafford Watts
University of Cambridge | Doctorate Degree |
The University of New South Wales | Undergraduate Degree |
Statistiche
Distribuzione geografica
Australia | 5 |
Regno Unito | 3 |
Posizioni
Director/Board Member | 4 |
Chairman | 1 |
Undergraduate Degree | 1 |
Settori
Consumer Services | 3 |
Health Technology | 3 |
Commercial Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 1 |
---|---|
ENERGY ACTION LIMITED | Commercial Services |
Aziende private | 3 |
---|---|
Biosceptre (Aust) Pty Ltd.
![]() Biosceptre (Aust) Pty Ltd. Pharmaceuticals: MajorHealth Technology Biosceptre (Aust) Pty Ltd. develops and commercializes antibody technologies for applications in the diagnosis and treatment of cancer. The company was founded in 2000 and is headquartered in North Ryde, Australia. | Health Technology |
Wenkart Foundation | |
Biosceptre International Ltd.
![]() Biosceptre International Ltd. BiotechnologyHealth Technology Part of Biosceptre (Aust) Pty Ltd., Biosceptre International Ltd. is a biopharmaceutical company based in Babraham, UK. The British company is focused on developing their BRiDGECAR™ system, which combines nfP2X7-targeted technology with highly potent chimeric antigen receptor (CAR) T-cell therapy and multiple targeted antibodies. The company's researchers are pioneers in cancer therapeutic development, with a vision of targeted treatment for millions of cancer patients across the world. The company's multi-targeted BRiDGECAR™ system has the potential to benefit a range of malignancies and make a drastic difference to the lives of millions of cancer patients. The company's advisory board includes Sir Gregory Winter, a 2018 Nobel Prize winner in Chemistry. | Health Technology |